A recurrent giant cell tumor of bone treated with denosumab

  • Nicola Stadler Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Thomas Fingernagel Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Stefan G. Hofstaetter Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Klemens Trieb | klemens.trieb@klinikum-wegr.at Department of Orthopaedics, Klinikum Wels-Grieskirchen, Wels, Austria.

Abstract

Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone after the implantation of a total endoprosthesis of the knee joint. We have treated her with denosumab, which is a receptor activator of nuclear factor kappa-B ligand inhibitor. In this case report we want to present a new option to treat this kind of neoplasm.

Downloads

Download data is not yet available.
Published
2015-02-10
Section
Case Reports
Keywords:
bone, denosumab, tumor.
Statistics
Abstract views: 1053

PDF: 379
HTML: 461
Share it
Bookmark and Share

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Stadler, N., Fingernagel, T., Hofstaetter, S. G., & Trieb, K. (2015). A recurrent giant cell tumor of bone treated with denosumab. Clinics and Practice, 5(1). https://doi.org/10.4081/cp.2015.697